Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial
Mixed: Mood and Mental Health Because GLP-1 receptors influence mood and factors like blood sugar, appetite, and sleep, and because rapid body changes also play a role, experiences vary widely
Both drugs have shown promising results in improving glycemic control and promoting weight loss, but their mechanisms and clinical profiles differ
Semaglutide is the same core drug behind three global brands:[8][3] Ozempic (injectable) approved in 2017 for type 2 diabetes, onceweekly injection.[9][3] Wegovy (higherdose injectable) approved in 2021 for chronic weight management, using larger doses of the same drug.[10][11] Rybelsus (oral tablet) an oral version of semaglutide, approved around 2019 for diabetes.[3][8] Clinically, the trials showed strong reductions in HbA1c and substantial weight loss versus older diabetes drugs and earlier weightloss pills.[12][13] Commercially, each brand got its own positioning, campaigns and, importantly, slightly different regulatory labels and patent wrapping.[14][15] Key point: One discovery was sliced into multiple brands and indications, each with its own story, price and protection
